Form 4: Denali Therapeutics CEO Ryan Watts Acquires Shares and Stock Options

Denali Therapeutics CEO Ryan Watts acquired 54,180 shares of common stock and 162,540 stock options, while also holding 2,202,604 shares indirectly through a family trust.

Summary

• Ryan Watts, the President and CEO of Denali Therapeutics, reported acquiring 54,180 shares of common stock through Restricted Stock Units (RSUs) and 162,540 stock options on January 3, 2025.
• The RSUs vest over four years, with 25% vesting on January 3, 2026, and the remaining 75% vesting annually thereafter.
• The stock options also vest over four years, with 25% vesting on January 3, 2026, and the remaining vesting monthly over the following 36 months.
• Mr. Watts also indirectly holds 2,202,604 shares through the Watts Family 2015 Trust.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally positive as it shows the CEO's continued investment in the company. There is no indication of any negative sentiment.

Positives

• The acquisition of shares and stock options by the CEO demonstrates confidence in the company's future performance.
• The vesting schedule of the RSUs and stock options aligns the CEO's interests with the long-term success of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The vesting schedules for the RSUs and stock options are typical for executive compensation packages in the biotechnology industry.
• Many companies use similar vesting schedules to incentivize long-term performance and retention of key personnel.
• The use of RSUs and stock options is a common practice for aligning executive interests with shareholder value.

Stakeholder Impact

• The transaction may have a slightly positive impact on shareholders as it demonstrates the CEO's confidence in the company.
• The vesting schedule of the RSUs and stock options aligns the CEO's interests with the long-term success of the company, which is beneficial for all stakeholders.

Key Dates

Keywords

Denali Therapeutics, Ryan Watts, stock options, restricted stock units, insider trading, executive compensation, share ownership